This event has ended. Showing historical data.

GroupKALSHI

Event GroupKALSHIScience and Technology

Will the FDA approve camizestrant for advanced breast cancer?

Total Volume

$0.00

Events

Markets

Trade on Kalshi

Will the FDA approve camizestrant for advanced breast cancer?

Vol

$0.00

Events

Markets

Kalshi

Platform StatsQuick Platform Comparison

Polymarket

markets · $0.00

Kalshi

markets · $0.00

Price Spread

0.0%avg

max 0.0%

Arbitrage

of 0 cross-platform

Price ChartMatched Markets Price Graph

3 markets tracked

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

No data available

Single-Platform Markets(3)

Market	Platform	Price
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?	Kalshi	74%
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?	Kalshi	61%
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?	Kalshi	32%

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

74%

Top Probability

$0.00

Volume

Markets

Platforms

About This Event

camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, X then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the

AI-generated analysis based on market data. Not financial advice.

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Monday, August 24, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** Will the FDA approve camizestrant for advanced breast cancer?
**Category:** Science and Technology | **Status:** active
**Resolution Date:** N/A (Unknown)
**Time Pressure:** Unknown

**Description:** camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, X then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the 

**Resolution Criteria (Sample):**
"If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, 2028, then the market resolves to Yes. Secondary rules: An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Lic"

## 2. Market liquidity & Volume
* **Total Volume:** $0
* **Total Liquidity:** $0
* **Activity Level:** Low Activity (Vol/Liq Ratio: 0.00)

## 3. Market Data (Prices & Odds)
### 1. Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?
- **Kalshi** (End: Jan 8, 2028): Vol $0
  DATA: [Yes: 73.5% (0.0%)] | [No: 26.5% (0.0%)]

### 2. Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?
- **Kalshi** (End: Jan 8, 2027): Vol $0
  DATA: [Yes: 61.0% (0.0%)] | [No: 39.0% (0.0%)]

### 3. Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?
- **Kalshi** (End: Oct 8, 2026): Vol $0
  DATA: [Yes: 32.5% (0.0%)] | [No: 67.5% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

KALSHIScience and Technology

Will the FDA approve camizestrant for advanced breast cancer?

Volume$0.00

Markets3

3 of 3

Sort:

KALSHI

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

KALSHI

KKalshi

Yes 73.5¢No 26.5¢

KALSHIHealth

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, 2028, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Lic

KALSHI

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?

KALSHI

KKalshi

Yes 61.0¢No 39.0¢

KALSHIHealth

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Lic

KALSHI

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?

KALSHI

KKalshi

Yes 32.5¢No 67.5¢

KALSHIHealth

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?

If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Oct 1, 2026, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics Lic

No related news found

Discussion

0 Comments

Market Insights

Average Yes Price

56¢

Kalshi

Arbitrage Opps

Cross-Platform

Embed Widget

Add this market to your website

Volume

Platforms

HTML

<iframe src="https://predictpedia.com/embed/n03Mlj" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="Will the FDA approve camizestrant for advanced breast cancer?"></iframe>

Trade This Market

Trade on Kalshi

Will the FDA approve camizestrant for advanced breast cancer?

Will the FDA approve camizestrant for advanced breast cancer?

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

AI Analysis

About This Event

Custom AI Analysis Prompt

Educational Context

Events (1)

Will the FDA approve camizestrant for advanced breast cancer?

Markets (3)

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?

Related News & Context

Discussion

Market Insights

Share

Embed Widget

Trade This Market

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

Custom AI Analysis Prompt

Will the FDA approve camizestrant for advanced breast cancer?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?

Related News & Context

Discussion

Share

Embed Widget